Unique ID issued by UMIN | UMIN000015410 |
---|---|
Receipt number | R000017919 |
Scientific Title | Clinical study of PepTivator(R) WT1-added autologous gamma/delta T cells therapy for cancer patients. |
Date of disclosure of the study information | 2014/10/10 |
Last modified on | 2017/08/31 11:11:25 |
Clinical study of PepTivator(R) WT1-added autologous gamma/delta T cells therapy for cancer patients.
Clinical study of PepTivator(R) WT1-added autologous gamma/delta T cells therapy for cancer patients.
Clinical study of PepTivator(R) WT1-added autologous gamma/delta T cells therapy for cancer patients.
Clinical study of PepTivator(R) WT1-added autologous gamma/delta T cells therapy for cancer patients.
Japan |
Patients who have malignant tumor with WT1-positive.
Patients who have ever received DC vaccination with WT1 peptide, or WT1 antigen.
Medicine in general | Gastroenterology | Hepato-biliary-pancreatic medicine |
Cardiology | Pneumology | Endocrinology and Metabolism |
Hematology and clinical oncology | Nephrology | Surgery in general |
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Vascular surgery |
Chest surgery | Endocrine surgery | Breast surgery |
Obstetrics and Gynecology | Dermatology | Oto-rhino-laryngology |
Urology | Oral surgery | Neurosurgery |
Malignancy
NO
To investigate safety and efficacy of PepTivator(R) WT1-pulsed autologous gamma/delta T cells.
Safety,Efficacy
Pragmatic
Not applicable
Safety
Immunological responses
Efficacy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
PepTivator(R) WT1-added Autologous gamma/delta T cells are injected on day0, day28.
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients with histologically confirmed malignant tumors.
2)Patients who recognized WT1 expression on tumor tissue.
Blood cancer patients who recognized WT1 expression in tumor cells.
3)Patients with a past history of a positive DTH.
4)Performance Status is 0-2.
5)No serious abnormality in bone marrow, liver, and renal functions.
6)Informed consent has been obtained .
Patients who have:
1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them
2)Serious drug allergy
3)Active autoimmune disease
4)Active enteritis
5)Positive for HIV or HTLV-1
6)Received continuous systemic steroids
7)Other cancers
8)Active infections
9)Serious cardiac disease
10)Pregnant or lactating
11)Any reason why, in the opinion of the investigator, the patient should not participate
5
1st name | |
Middle name | |
Last name | Takashi Kamigaki |
Seta Clinic Group
Center for Clinical Trials and Research
3F New Surugadai Bldg.2-1-45 Kandasurugadai, Chiyoda-ku Tokyo, 102-0062 JAPAN
03-5244-5751
kamigaki@j-immunother.com
1st name | |
Middle name | |
Last name | Hiroshi Ibe |
Seta Clinic Group
Center for Clinical Trials and Research
3F New Surugadai Bldg.2-1-45 Kandasurugadai, Chiyoda-ku Tokyo, 102-0062 JAPAN
03-5244-5751
scrc@j-immunother.com
Seta Clinic Group
Medinet Co.,Ltd.
Profit organization
NO
瀬田クリニックグループ
2014 | Year | 10 | Month | 10 | Day |
Unpublished
Completed
2014 | Year | 09 | Month | 30 | Day |
2014 | Year | 10 | Month | 10 | Day |
2014 | Year | 10 | Month | 10 | Day |
2017 | Year | 08 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017919
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |